Tanaka et al., 1983 - Google Patents

A new radiopharmaceutical: 99m Tc DMP for renal scanning

Tanaka et al., 1983

Document ID: 2272114593389120473
Author: Tanaka A; Machida T; Miki M; Shimada T
Publication year: 1983
Publication venue: European Journal of Nuclear Medicine

External Links

Cited by

Snippet

Abstract 99m Tc-Dimercaptopropionic acid (DMP), a new renal scanning agent was synthesized, and the optimum preparative conditions and stability of this compound were determined. It was demonstrated that scans performed with this agent in rats showed highly …

Continue reading at link.springer.com (other versions)

230000000268 renotropic 0 title abstract description 26

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0497—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds conjugates with a carrier being an organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K2123/00—Preparations for testing in vivo

Similar Documents

Publication	Publication Date	Title
Verbruggen et al.	1992	Technetium-99m-L, L-ethylenedicysteine: a renal imaging agent. I. Labeling and evaluation in animals
Loberg et al.	1976	Development of new radiopharmaceuticals based on N-substitution of iminodiacetic acid
US4387087A (en)	1983-06-07	Cationic lipophilic complexes of 99m Tc and their use for myocardial and hepatobiliary imaging
CA2054263C (en)	2001-05-29	Process for preparing a radiopharmaceutical composition
Boniface et al.	1989	Labeling of monoclonal antibodies with samarium-153 for combined radioimmunoscintigraphy and radioimmunotherapy
Baldas et al.	1985	Effect of the Tc-nitrido group on the behaviour of 99mTc-radiopharmaceuticals
KR850001871B1 (en)	1985-12-28	A process for preparing non-radioactive carrier composition and radioactive diagnostic agent therefrom
US4489054A (en)	1984-12-18	Cationic lipophilic complexes of 99m Tc and their use for myocardial and hepatobiliary imaging
Tanaka et al.	1983	A new radiopharmaceutical: 99m Tc DMP for renal scanning
Fritzberg et al.	1976	99mTc-bioquin-7CA, a potential new hepatobiliary scanning agent
JPH0653750B2 (en)	1994-07-20	Tris (isonitrile) copper (1) adducts for preparing radionuclide complexes
Bormans et al.	1992	Evaluation of 99mTc-mercaptoacetyltripeptides in mice and a baboon
KARUBE et al.	1983	Evaluation of 99mTc-labeled amino acids as radiopharmaceuticals. V. 99mTc complex of ethylenediamine-N, N-diacetic acid as a scintigraphic agent for tumors
US3749913A (en)	1973-07-31	Renal scanning composition and method using technetium 99m
Wang et al.	1995	Evaluation of the biodistribution and in vivo biochemistry of 99mTc-cysteine and 99/99mTc-cysteine complexes—A potential renal imaging agent
Hinkle et al.	1981	Kit preparation of radioiodinated o‐iodohippuran
Jansholt et al.	1978	Catabolism and protein binding of Tc-99m pyridoxylideneglutamate
AU609569B2 (en)	1991-05-02	Tc-99m mononuclide complex compound
Thornback et al.	1981	Technetium-99m-Ethylenediamine: A new cationic complex of technetium
Özker et al.	1981	99m Tc-gentamicin: Chemical and biological evaluation
CA2066779A1 (en)	1991-03-23	Stable therapeutic radionuclide compositions and methods for preparation thereof
WO1990005543A2 (en)	1990-05-31	Tumor imaging with technetium labeled carbohydrates
Zhang et al.	2002	Preparation, characterization and biodistribution of a new technetium‐99 m nitrido complex with 2‐methoxyisobutylisonitrile and comparison with 99mTc–MIBI
Bormans et al.	1992	Evaluation of the renal excretion characteristics of technetium-99m mercaptoacetylglycyl-D-alanylglycine in healthy volunteers
Mukherjee et al.	1993	Cysteine, a chelating moiety for synthesis of technetium-99m radiopharmaceuticals—Part IV. Benzyl cysteine and derivatives